-
公开(公告)号：US10792299B2
公开(公告)日：2020-10-06
申请号：US15434318
申请日：2017-02-16
发明人： Kenjirou Minomi , Jihua Liu , Li Wang , Bharat Majeti , Roger Adami , Wenbin Ying
IPC分类号： A61K31/713 , A61K31/7105 , C12N15/113 , A61K9/51
摘要： This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.
-
公开(公告)号：US20200085957A1
公开(公告)日：2020-03-19
申请号：US16460812
申请日：2019-07-02
发明人： Joseph E. Payne , John A. Gaudette , Zheng Hou , Mohammad Ahmadian , Lei Yu , Victor Knopov , Violetta Akopian , Priya Karmali , Richard P. Witte , Neda Safarzadeh , Wenbin Ying , Jun Zhang
IPC分类号： A61K47/20 , C07C323/60 , C07D333/38 , C07C271/16 , C07D333/40 , C07C317/44 , C07C333/04 , C07C235/08 , C07C237/08 , C07D207/16 , A61K47/14 , A61K9/127 , A61K47/18 , A61K47/22 , C07C237/16
摘要： The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.
-
公开(公告)号：US20190231695A1
公开(公告)日：2019-08-01
申请号：US16377032
申请日：2019-04-05
发明人： Roger Adami , Yuwei Wang , Haiqing Yin , Liping Wang , Dong Liu , Wenbin Ying
IPC分类号： A61K9/19 , A61K31/713 , A61K9/51 , A61K9/127 , A61K47/40 , A61K47/36 , A61K9/14 , C12N15/11 , A61K47/26 , C12N15/113
CPC分类号： A61K9/19 , A61K9/1271 , A61K9/145 , A61K9/146 , A61K9/5123 , A61K31/713 , A61K47/26 , A61K47/36 , A61K47/40 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2320/32
摘要： This invention provides compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides.
-
公开(公告)号：US20190133948A1
公开(公告)日：2019-05-09
申请号：US16182571
申请日：2018-11-06
发明人： Kwok Tsang , Bharat Majeti , John Gaudette , Roger Adami , Hao Bai , Wenbin Ying
摘要： This invention includes fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.
-
公开(公告)号：US10196637B2
公开(公告)日：2019-02-05
申请号：US15284494
申请日：2016-10-03
发明人： Yoshiro Niitsu , Victor Knopov , Joseph E. Payne , Richard P. Witte , Mohammad Ahmadian , Loren A. Perelman , Violetta Akopian , Yasunobu Tanaka , Elena Feinstein , Sharon Avkin-Nahum , Hagar Kalinski , Igor Mett , Kenjiro Minomi , Wenbin Ying , Yun Liu , Zheng Hou , John A. Gaudette , Priya Karmali , Sridhar C. Nagarajan
IPC分类号： C12N15/113 , A61K31/713 , A61K47/18 , A61K47/24 , A61K9/127 , C07H21/02 , C12N15/11 , A61K45/06
摘要： What is described is a pharmaceutical composition for treating a fibrotic disease comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.
-
公开(公告)号：US20180002702A1
公开(公告)日：2018-01-04
申请号：US15636528
申请日：2017-06-28
发明人： Kenjirou Minomi , Jihua Liu , Li Wang , Bharat Majeti , Roger Adami , Wenbin Ying
IPC分类号： C12N15/113 , A61K9/127 , A61K31/713
CPC分类号： C12N15/1137 , A61K9/127 , A61K31/7105 , A61K31/713 , C12N15/113 , C12N15/1135 , C12N2310/14 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/531 , C12N2320/32 , C12Y205/01018 , C12N2310/3521
摘要： This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor, which may be associated with KRAS mutation in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.
-
公开(公告)号：US20170175115A1
公开(公告)日：2017-06-22
申请号：US15283179
申请日：2016-09-30
发明人： Yoshiro Niitsu , Victor Knopov , Joseph E. Payne , Richard P. Witte , Mohammad Ahmadian , Loren A. Perelman , Violetta Akopian , Yasunobu Tanaka , Elena Feinstein , Sharon Avkin-Nahum , Hagar Kalinski , Igor Mett , Kenjiro Minomi , Wenbin Ying , Yun Liu
IPC分类号： C12N15/113
CPC分类号： A61K9/1271 , A61K9/127 , A61K31/713 , C07H21/02 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2320/32 , C12N2320/52
摘要： What is described is a method for treating a fibrotic disease by administering a pharmaceutical composition comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.
-
48.发明授权Methods and compositions for treating malignant tumors associated with KRAS mutation 有权用于治疗与KRAS突变相关的恶性肿瘤的方法和组合物公开(公告)号：US09580710B2
公开(公告)日：2017-02-28
申请号：US14979573
申请日：2015-12-28
发明人： Kenjirou Minomi , Jihua Liu , Li Wang , Bharat Majeti , Roger Adami , Wenbin Ying
IPC分类号： C07H21/02 , A61K48/00 , C12N15/113
CPC分类号： C07F9/6533 , A61K31/713 , C12N15/113 , C12N15/1135 , C12N15/1137 , C12N2310/14 , C12N2310/322 , C12N2310/344 , C12N2310/3515 , C12N2310/531 , C12N2320/30 , C12N2320/32 , C12N2320/35 , C12N2320/53 , C12Q1/02 , G01N33/582 , H05K999/99 , C12N2310/3533 , C12N2310/3531 , C12N2310/321 , C12N2310/3521
摘要： This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.
摘要翻译： 本发明提供了通过鉴定哺乳动物的肿瘤细胞来预防，治疗或改善与有需要的哺乳动物有关的KRAS突变相关的恶性肿瘤的一种或多种症状的方法和组合物，所述肿瘤细胞包含以下至少一种：（ i）KRAS基因的突变，和（ii）KRAS蛋白的异常表达水平; 以及向哺乳动物施用治疗有效量的包含一种或多种在减少GST-π表达中有活性的RNAi分子的组合物。
-
公开(公告)号：US20160376229A1
公开(公告)日：2016-12-29
申请号：US15191511
申请日：2016-06-23
发明人： Roger Adami , Hao Bai , John Gaudette , Bharat Majeti , Seiji Nukui , Kwok Yin Tsang , Hai Wang , Haiqing Ying , Wenbin Ying
IPC分类号： C07C271/16 , A61K47/22 , C07D207/12 , A61K47/16 , C07C237/16 , A61K31/713 , C07D211/86 , C07D211/82 , C07D211/74 , C07F9/06 , A61K47/24 , C07D205/04 , C07D207/09
CPC分类号： C07C271/16 , A61K9/127 , A61K9/5123 , A61K31/7105 , A61K31/713 , C07C237/08 , C07C237/16 , C07C237/50 , C07D205/04 , C07D207/09 , C07D207/12 , C07D211/74 , C07D211/82 , C07D211/86 , C07F9/06 , C07F9/106 , A61K2300/00
摘要： This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.
摘要翻译： 本发明包括可离子化的化合物及其组合物及其使用方法。 可电离化合物可用于制备用于生物药物和治疗剂的纳米颗粒组合物。 更具体地说，本发明涉及用于提供纳米颗粒以包封活性剂（例如核酸试剂）的化合物，组合物和方法，并将活性剂递送和分配到细胞，组织，器官和受试者中。
-
公开(公告)号：US20160074514A1
公开(公告)日：2016-03-17
申请号：US14872951
申请日：2015-10-01
发明人： Joseph E. Payne , John A. Gaudette , Zheng Hou , Mohammad Ahmadian , Lei Yu , Victor Knopov , Violetta Akopian , Priya Karmali , Richard P. Witte , Neda Safarzadeh , Wenbin Ying , Jun Zhang
IPC分类号： A61K47/18 , C07C237/16 , C07C323/60 , C07C317/44 , A61K9/127 , C07D333/38 , A61K47/20 , A61K47/22 , C07D207/16 , C07C237/08 , C07C333/04
摘要： The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.
摘要翻译： 该描述针对可用于增强脂质体中治疗剂递送的可离子化脂质。
-
-
-
-
-
-
-
-
-
搜索结果
64 条记录 (耗时 0.047 秒)
